Abstract
In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.
| Original language | English |
|---|---|
| Pages (from-to) | 69-82 |
| Number of pages | 14 |
| Journal | Korean journal of radiology |
| Volume | 20 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2019 Jan |
Fingerprint
All Science Journal Classification (ASJC) codes
- Radiology Nuclear Medicine and imaging
Cite this
}
Introduction of a new staging system of breast cancer for radiologists : An emphasis on the prognostic stage. / Koh, Jieun; Kim, Min Jung.
In: Korean journal of radiology, Vol. 20, No. 1, 01.2019, p. 69-82.Research output: Contribution to journal › Editorial
TY - JOUR
T1 - Introduction of a new staging system of breast cancer for radiologists
T2 - An emphasis on the prognostic stage
AU - Koh, Jieun
AU - Kim, Min Jung
PY - 2019/1
Y1 - 2019/1
N2 - In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.
AB - In 2017, the American Joint Committee on Cancer announced the 8th edition of its cancer staging system. For breast cancer, the most significant change in the staging system is the incorporation of biomarkers into the anatomic staging to create prognostic stages. Different prognostic stages are assigned to tumors with the same anatomic stages according to the tumor grade, hormone receptor (estrogen receptor; progesterone receptor) status, and HER2 status. A Clinical Prognostic Stage is assigned to all patients regardless of the type of therapy used; in contrast, a Pathologic Prognosis Stage is assigned to patients in whom surgery is the initial treatment. In a few situations, low Oncotype DX recurrence scores can change the prognostic stage. The radiologists need to understand the importance of the biologic factors that can influence cancer staging.
UR - http://www.scopus.com/inward/record.url?scp=85059645475&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059645475&partnerID=8YFLogxK
U2 - 10.3348/kjr.2018.0231
DO - 10.3348/kjr.2018.0231
M3 - Editorial
C2 - 30627023
AN - SCOPUS:85059645475
VL - 20
SP - 69
EP - 82
JO - Korean Journal of Radiology
JF - Korean Journal of Radiology
SN - 1229-6929
IS - 1
ER -